Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Carcinoma, Transitional Cell × dactolisib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 5 Neoplasms 3 Neuroendocrine Tumors 2 Neuroectodermal Tumors, Primitive 2 Neoplasm Metastasis 2 Glioblastoma 2 Carcinoma, Renal Cell 2 Uterine Neoplasms 1 Tuberous Sclerosis 1 Triple Negative Breast Neoplasms 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Perivascular Epithelioid Cell Neoplasms 1 Pancreatic Neoplasms 1 Malignant Solid Tumour 1 Leukemia, Myeloid, Acute 1 Kidney Neoplasms 1 Hamartoma Syndrome, Multiple 1 Gliosarcoma 1 Endometrial Neoplasms 1 Castration-resistant Prostate Cancer 1 Carcinoma, Transitional Cell 1 Breast Diseases 1 Brain Neoplasms 1 Angiomyolipoma 1

Interventions

pembrolizumab 70 Gemcitabine 44 Nivolumab 36 Cisplatin 32 atezolizumab 31 Carboplatin 25 avelumab 24 enfortumab vedotin 21 Docetaxel 20 Magnetic Resonance Spectroscopy 16 Mitomycin 14 Ipilimumab 14 Paclitaxel 13 Specimen Handling 11 durvalumab 10 toripalimab 8 sacituzumab govitecan 8 vinflunine 7 cabozantinib 7 Pemetrexed 7 Injections 6 Cyclophosphamide 6 Bevacizumab 6 tislelizumab 5 pemigatinib 5 Taxes 5 Fluorodeoxyglucose F18 5 Biopsy 5 lenvatinib 4 fludarabine 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01856101 2019-04-10

BEZ235

Cliniques universitaires Saint-Luc- Université Catholique de Louvain

Phase 2 Terminated

Carcinoma, Transitional Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡